Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)

Santhera Pharmaceuticals

Overview

The objective of the study is to determine whether administration of idebenone can shorten the time to improvement of visual acuity in patients with chronic vision loss due to LHON.

Study Type

INTERVENTIONAL

Conditions

Leber's Hereditary Optic Neuropathy

Interventions

IdebenoneDRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 10 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> or equal 10 years and \< 65 years * Impaired visual acuity in affected eyes due to LHON: Visual acuity in best eye \>0.4 logMAR * No explanation for visual loss besides LHON Exclusion Criteria: * Any previous use of idebenone * Participation in another clinical trial of any investigational drug within 3 months prior to Baseline * Previous participation in Study SNT-II-003 (RHODOS) for idebenone.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.